FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2223432694> ?p ?o ?g. }

• W2223432694 endingPage "e29" @default.
• W2223432694 startingPage "e22" @default.
• W2223432694 abstract "T-cell large granular lymphocytic leukaemia (T-LGL) is a lymphoproliferative disease that presents with immune-mediated cytopenias and is characterised by clonal expansion of cytotoxic CD3+ CD8+ lymphocytes. Use of methotrexate, ciclosporin, or cyclophosphamide as first therapy improves cytopenias in 50% of patients, but long-term use of these can lead to toxicity. We aimed to explore the activity and safety of alemtuzumab, an anti-CD52 monoclonal antibody, in patients with T-LGL.We did this single-arm, phase 2 trial in consecutively enrolled adults with T-LGL referred to the National Institutes of Health in Bethesda, MD, USA. Alemtuzumab was given intravenously at 10 mg per day for 10 days. The primary endpoint was haematological response at 3 months after infusion. A complete response was defined as normalisation of all affected lineages, and a partial response was defined in neutropenic patients as 100% increase in the absolute neutrophil count to more than 5 × 10(8) cells per L, and in those with anaemia, as any increase in haemoglobin of 20 g/L or higher observed in at least two serial measurements 1 week apart and sustained for 1 month or longer without exogenous growth factors support or transfusions. Analysis was by intention to treat. We report results from the first stage of this Simon two-stage design trial; enrolment into the second stage is continuing. This study is registered with ClinicalTrials.gov, number NCT00345345.From Oct 1, 2006, to March 1, 2015, we enrolled 25 patients with T-LGL. 14 patients (56%; 95% CI 35-76) had a haematological response at 3 months. Four patients with associated myelodysplastic syndrome and two who had received haemopoietic stem cell transplantation had either no response or were not evaluable, meaning 14 (74% [49-91]) of the 19 patients with classic T-LGL responded. All patients had an infusion reaction (24 [96%] patients grade 1-2, one [4%] patient grade 3), which improved with symptomatic therapy. All patients developed lymphopenia, with 22 (88%) patients having grade 3 or 4 lymphopenia. The other most common grade 3 and 4 adverse events were leukopenia (eight [32%]) and neutropenic infections (five [20%]). Seven patients died; all were non-responders.This is the largest and only prospective study of alemtuzumab in patients with T-LGL. The activity reported with a single course of a lymphocytotoxic drug in patients with mainly relapsed and refractory disease suggests that haematological response can be achieved without continued use of oral immunosuppression.National Heart, Lung, and Blood Institute." @default.
• W2223432694 created "2016-06-24" @default.
• W2223432694 creator A5001563093 @default.
• W2223432694 creator A5004581558 @default.
• W2223432694 creator A5015491576 @default.
• W2223432694 creator A5019177042 @default.
• W2223432694 creator A5024701461 @default.
• W2223432694 creator A5025683999 @default.
• W2223432694 creator A5026597677 @default.
• W2223432694 creator A5029569639 @default.
• W2223432694 creator A5031839073 @default.
• W2223432694 creator A5032718078 @default.
• W2223432694 creator A5043902228 @default.
• W2223432694 creator A5049066393 @default.
• W2223432694 creator A5071703277 @default.
• W2223432694 creator A5072063614 @default.
• W2223432694 creator A5074515375 @default.
• W2223432694 creator A5075319144 @default.
• W2223432694 creator A5079533727 @default.
• W2223432694 creator A5079704265 @default.
• W2223432694 creator A5080201916 @default.
• W2223432694 creator A5081398715 @default.
• W2223432694 creator A5081836686 @default.
• W2223432694 date "2016-01-01" @default.
• W2223432694 modified "2023-10-01" @default.
• W2223432694 title "Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study" @default.
• W2223432694 cites W1967324333 @default.
• W2223432694 cites W1971231003 @default.
• W2223432694 cites W1974074731 @default.
• W2223432694 cites W1979207587 @default.
• W2223432694 cites W1987819921 @default.
• W2223432694 cites W2001611608 @default.
• W2223432694 cites W2011572042 @default.
• W2223432694 cites W2016106209 @default.
• W2223432694 cites W2017871874 @default.
• W2223432694 cites W2029409133 @default.
• W2223432694 cites W2038940923 @default.
• W2223432694 cites W2040344915 @default.
• W2223432694 cites W2041204531 @default.
• W2223432694 cites W2051743376 @default.
• W2223432694 cites W2057215007 @default.
• W2223432694 cites W2059045334 @default.
• W2223432694 cites W2062558627 @default.
• W2223432694 cites W2064437809 @default.
• W2223432694 cites W2080349789 @default.
• W2223432694 cites W2085822471 @default.
• W2223432694 cites W2087505144 @default.
• W2223432694 cites W2090141341 @default.
• W2223432694 cites W2092594443 @default.
• W2223432694 cites W2094111973 @default.
• W2223432694 cites W2105914383 @default.
• W2223432694 cites W2124727014 @default.
• W2223432694 cites W2140800418 @default.
• W2223432694 cites W2141253976 @default.
• W2223432694 cites W2148766438 @default.
• W2223432694 cites W2152526557 @default.
• W2223432694 cites W2158202057 @default.
• W2223432694 cites W2165954541 @default.
• W2223432694 doi "https://doi.org/10.1016/s2352-3026(15)00227-6" @default.
• W2223432694 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4721315" @default.
• W2223432694 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26765645" @default.
• W2223432694 hasPublicationYear "2016" @default.
• W2223432694 type Work @default.
• W2223432694 sameAs 2223432694 @default.
• W2223432694 citedByCount "33" @default.
• W2223432694 countsByYear W22234326942017 @default.
• W2223432694 countsByYear W22234326942018 @default.
• W2223432694 countsByYear W22234326942019 @default.
• W2223432694 countsByYear W22234326942020 @default.
• W2223432694 countsByYear W22234326942021 @default.
• W2223432694 countsByYear W22234326942022 @default.
• W2223432694 countsByYear W22234326942023 @default.
• W2223432694 crossrefType "journal-article" @default.
• W2223432694 hasAuthorship W2223432694A5001563093 @default.
• W2223432694 hasAuthorship W2223432694A5004581558 @default.
• W2223432694 hasAuthorship W2223432694A5015491576 @default.
• W2223432694 hasAuthorship W2223432694A5019177042 @default.
• W2223432694 hasAuthorship W2223432694A5024701461 @default.
• W2223432694 hasAuthorship W2223432694A5025683999 @default.
• W2223432694 hasAuthorship W2223432694A5026597677 @default.
• W2223432694 hasAuthorship W2223432694A5029569639 @default.
• W2223432694 hasAuthorship W2223432694A5031839073 @default.
• W2223432694 hasAuthorship W2223432694A5032718078 @default.
• W2223432694 hasAuthorship W2223432694A5043902228 @default.
• W2223432694 hasAuthorship W2223432694A5049066393 @default.
• W2223432694 hasAuthorship W2223432694A5071703277 @default.
• W2223432694 hasAuthorship W2223432694A5072063614 @default.
• W2223432694 hasAuthorship W2223432694A5074515375 @default.
• W2223432694 hasAuthorship W2223432694A5075319144 @default.
• W2223432694 hasAuthorship W2223432694A5079533727 @default.
• W2223432694 hasAuthorship W2223432694A5079704265 @default.
• W2223432694 hasAuthorship W2223432694A5080201916 @default.
• W2223432694 hasAuthorship W2223432694A5081398715 @default.
• W2223432694 hasAuthorship W2223432694A5081836686 @default.
• W2223432694 hasBestOaLocation W22234326942 @default.
• W2223432694 hasConcept C126322002 @default.
• W2223432694 hasConcept C167672396 @default.
• W2223432694 hasConcept C203014093 @default.

• next